GlassScriptPhysician profile
David K Haseltine
NPI 1396747820
$1,026.42
in general payments reported to CMS, 2019-2025
21 companies · $31.42 in 2025
The $31.42 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.39 · 2021: $90.23 · 2022: $348 · 2023: $279 · 2024: $246 · 2025: $31.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $122.31 | 2023-2024 | Freestyle Libre |
| Novo Nordisk INC | $104.73 | 2022-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $95.07 | 2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $79.45 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $76.52 | 2022-2025 | Verquvo, Belsomra, Capvaxive |
| Glaxosmithkline, LLC. | $64.65 | 2021-2024 | Trelegy Ellipta |
| Amarin Pharma, INC. | $60.09 | 2021-2022 | |
| Abbvie INC. | $52.82 | 2022-2024 | |
| Nevro Corp. | $51.10 | 2024 | Senza |
| Supernus Pharmaceuticals, INC. | $46.80 | 2022 | |
| Corcept Therapeutics | $43.83 | 2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $41.86 | 2022 | |
| Amgen INC. | $28.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $27.99 | 2022-2024 | Farxiga |
| Lilly USA, LLC | $27.20 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $23.82 | 2023 | Gemtesa |
| Cvrx, INC. | $17.90 | 2024 | Barostim Neo System |
| Daiichi Sankyo INC. | $17.48 | 2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $15.62 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.46 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.79 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Haseltine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.